# Expanded Access Protocol for Boys With Duchenne Muscular Dystrophy

> **NCT03863119** · — · AVAILABLE · sponsor: **Santhera Pharmaceuticals**

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** Vamorolone

## Key facts

- **NCT ID:** NCT03863119
- **Lead sponsor:** Santhera Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03863119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03863119, "Expanded Access Protocol for Boys With Duchenne Muscular Dystrophy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03863119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*